Personalized mRNA Melanoma Vaccine Cuts Recurrence Risk 42% in Phase 3 Trial

A personalized mRNA cancer vaccine cut the risk of melanoma returning or killing patients by 42 percent when added to standard immunotherapy, according to phase 3 trial results presented this week at the European Society for Medical Oncology Congress in Madrid.

The vaccine, intismeran autogene, was developed by Moderna and Merck. It works by reading the genetic fingerprint of each patient's tumor after surgery and building a custom mRNA sequence targeting that person's specific cancer mutations, what researchers call a neoantigen approach. Patients in INTerpath-001 received it alongside pembrolizumab, the checkpoint inhibitor already used as standard adjuvant therapy for high-risk resected melanoma, and were compared against patients receiving pembrolizumab plus placebo.

According to a press release reviewed by Merck, the trial enrolled 1,137 patients with completely resected stage IIB through stage IV cutaneous melanoma, randomized two-to-one in favor of the combination arm. At a median follow-up of 24.6 months, the vaccine-plus-pembrolizumab group hit a two-year recurrence-free survival rate of 82.2 percent, compared with 70 percent for pembrolizumab alone. In plain terms, roughly 12 more patients out of every 100 were alive and cancer-free at the two-year mark.

The trial also met its key secondary endpoint. According to data presented at ESMO 2026, the combination reduced the risk of distant metastasis or death by 38 percent, with a two-year distant metastasis-free survival rate of 88.5 percent versus 80.2 percent for immunotherapy alone.

The companies reported no new safety signals in the combination arm, which matters for a treatment that runs on top of a drug already known for immune-related side effects. That said, overall survival data are still maturing, and longer follow-up will be needed before oncologists can say whether the recurrence benefit translates to a survival advantage at the population level.

What makes INTerpath-001 structurally different from the many vaccine trials that have fallen short is the study design itself. According to experts reacting to the abstract via the Science Media Centre, the trial was a large, randomized, double-blind, well-controlled study, the kind of evidence that regulators actually move on. This is also, according to a joint statement reviewed from Merck and Moderna, the first phase 3 study to show a clinically meaningful improvement over pembrolizumab alone in the adjuvant melanoma setting, and the first positive phase 3 readout for any individualized neoantigen therapy.

The backdrop matters here. Melanoma that's caught early and surgically removed can still recur, and the patients enrolled in this trial were already at high risk of that happening. Stage IIB through stage IV disease after resection is not a benign situation, and pembrolizumab alone, while effective, still leaves a meaningful percentage of patients vulnerable. The vaccine is trying to pick up the slack by training the immune system on tumor-specific targets the checkpoint inhibitor alone doesn't address.

For patients, the practical question is when this becomes available. Merck and Moderna haven't announced a regulatory filing timeline, and manufacturing a custom mRNA therapy for each individual patient is not the same logistical lift as producing a standard drug. The companies have said they're in discussions with regulators, but there's no approval date on the table yet. Clinicians should expect that if approval does come, access will be concentrated at academic and large community cancer centers first, not every infusion suite.

Previous phase 2b data presented at the 2026 ASCO Annual Meeting showed a 49 percent reduction in recurrence risk at five years, according to results cited in a Dermatology Times report. The phase 3 numbers at two years are modestly lower, which is worth watching as the follow-up extends. The trajectory from early-phase excitement to phase 3 confirmation, though, is exactly the direction this field needed.

Sources cited:
- Merck Press Release (via Merck.com) (https://www.merck.com/news/merck-and-moderna-will-present-results-from-landmark-phase-3-interpath-001-trial-for-intismeran-autogene-plus-keytruda-pembrolizumab-at-esmo-2026-presidential-symposium/)
- AACR Blog (https://www.aacr.org/blog/2026/10/26/from-promise-to-proof-personalized-melanoma-mrna-vaccine-delivers-phase-iii-success/)
- Science Media Centre expert reaction (https://www.sciencemediacentre.org/expert-reaction-to-abstract-of-phase-3-interpath-001-trial-results-of-an-individualised-mrna-vaccine-for-resected-stage-iib-iv-melanoma-due-to-be-presented-at-esmo/)
- Dermatology Times (https://www.dermatologytimes.com/view/personalized-mrna-based-melanoma-vaccine-meets-primary-endpoints-in-landmark-phase-3-trial)
- PubMed / Cancer Discovery (https://pubmed.ncbi.nlm.nih.gov/42929716/)